Bladder carcinoma in situ
MONDO:0004703Also known as carcinoma in situ of the urinary bladder or high grade intraurothelial neoplasia, this is a flat lesion of the transitional cell epithelium characterized by severe cytologic atypia. This lesion is confined to the urothelium, and is a precursor of invasive transitional cell carcinoma of the bladder. Stage 0is includes: Tis, N0, M0. Tis: Carcinoma in situ: "flat tumor". N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 6th and 7th eds.)
Also known as: cancer in situ of urinary bladder, bladder flat CIS, bladder flat carcinoma in situ, carcinoma in situ of bladder, carcinoma in situ of the urinary bladder, carcinoma in situ of urinary bladder, flat CIS of the bladder, flat CIS of the urinary bladder
2807 clinical trials for this condition and its sub-types, 30 tagged with Bladder carcinoma in situ itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →-
New hope for tough bladder cancer: immune drug plus chemo combo enters trial
Disease control Not yet recruitingThis study tests whether adding chemotherapy drugs (gemcitabine and mitomycin C) directly into the bladder alongside an immune-boosting drug (toripalimab) works better than toripalimab alone for people with a high-risk bladder cancer that did not respond to standard BCG therapy. …
Phase 2 • Sponsor: First Affiliated Hospital of Wenzhou Medical University • Aim: Disease control
Last updated Sep 10, 2026 00:00 UTC
-
New bladder cancer drug could spare patients from bladder removal
Disease control Not yet recruitingThis Phase 3 trial tests NDV-01, a sustained-release combination of two chemotherapy drugs (gemcitabine and docetaxel), given directly into the bladder. It aims to prevent cancer from coming back in people with non-muscle invasive bladder cancer, including those who have not resp…
Phase 3 • Sponsor: Relmada Therapeutics, Inc. • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
Can a Bladder-Instilled biologic keep recurrent bladder cancer at bay?
Disease control Not yet recruitingThis early-phase trial is testing a new biologic drug, UGN-501, for people whose non-muscle invasive bladder cancer has returned after previous treatment. The drug is given directly into the bladder through a catheter once a week for six weeks, with possible quarterly maintenance…
Phase 1 • Sponsor: UroGen Pharma, Inc., a subsidiary of UroGen Pharma Ltd. • Aim: Disease control
Last updated Jul 26, 2026 00:00 UTC
-
Heated chemo offers new hope for bladder cancer patients facing surgery
Disease control Not yet recruitingThis study tests a treatment called HIVEC, which delivers heated chemotherapy directly into the bladder. It is for people with a type of bladder cancer that has not responded to standard therapy and who cannot have their bladder removed. The goal is to see if this approach is saf…
Sponsor: AC.TA. S.r.l. • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC